20772-13-8

Usage

Class

Ketone

Physical State

Colorless solid

Odor

Characteristic

Usage

Key intermediate in the synthesis of pharmaceuticals and illicit drugs (e.g., methamphetamine and MDMA)

Synthesis

Ease of synthesis and availability of precursor chemicals

Application

Commonly utilized in clandestine drug manufacturing

Regulation

Monitored by various governmental agencies to prevent illegal production and trafficking

Health Risks

Respiratory irritation, skin and eye irritation, central nervous system effects

Upstream product

• 186581-53-3 diazomethane 
• 4693-91-8 4-methoxyphenyl-acetic chloride 
• 104-01-8 4-Methoxyphenylacetic acid 

Downstream Products

• 104554-99-6 Oxalsaeure-(ethyl)<3-(4-methoxyphenyl)-2-oxopropyl>ester 
• 774-41-4 1-bromo-1-(4-methoxyphenyl)propan-2-one 
• 179018-45-2 4-[(4-methoxyphenyl)methyl]thiazole 
• 179018-46-3 4-(4-thiazolylmethyl)phenol 
• 41744-32-5 grevillin A 
• 41744-33-6 grevillin B 
• 40683-42-9 Tetra-O-acetylgrevillin B 
• 104555-16-0 3-methoxy-4-(4'-methoxyphenyl)-6-(4''-methoxyphenyl)methylene-2H-pyran-2,5(6H)-dione 
• 104555-17-1 6-(3',4'-dimethoxyphenyl)methylene-3-methoxy-4-(4''-methoxyphenyl)-2H-pyran-2,5(6H)-dione 
• 104555-01-3 3-Hydroxy-4-(4-methoxyphenyl)-2H-pyran-2,5(6H)-dion 
• 104555-15-9 3-Hydroxy-4-(4-methoxyphenyl)-6-(3-phenylpropenyliden)-2H-pyran-2,5(6H)-dion 
• 104555-10-4 3-Hydroxy-6-(3-hydroxybenzyliden)-4-(4-methoxyphenyl)-2H-pyran-2,5(6H)-dion 
• 104555-04-6 4'-O-Methylgrevillin A 
• 104555-03-5 4',4-Di-O-methylgrevillin A 

Relevant academic research and scientific papers

MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF

Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.

2-Arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands

The invention concerns novel 2-arylimino-2,3-dihydrothiazole derivatives of general formula (I), their preparation methods and their use as medicines, in particular for treating pathological conditions or diseases wherein one (or several) somatostatin receptors is/are involved. Said pathological conditions include in particular acromegaly, pituitary adenoma or endocrine gastroenteropanceatic tumors including the carcinoid syndrome, and gastrointestinal bleeding. In general formula (I), R1 represents in particular an alkyl, aralkyl, cyclohexyl radical optionally substituted by an amino radical or R1 represents a —C(R11)(R12)—CO—R10 radical wherein R11 represents H, R12 represents in particular H, carbocyclic or heterocyclic alkyl, cycloalkyl or aralkyl and R10 represents in particular an aminoalkylamino radical; R2 represents a carcyclic or heterocyclic aryl radical optionally substituted; R3 represents in particular COR5 or a carbocyclic or heterocyclic alkyl, adamantyl, aryl radical optionally substituted, carbocyclic or heterocyclic aralkyl optionally substituted on the aryl group; and R5 represents a radical fixed by a nitrogen atom to the group CO.

LTA4 Hydrolase inhibitors

The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as proriasis, ulcerative colitis, IBD and asthma.

Structure-activity relationship studies on 1-[2-(4- phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A4 (LTA4) hydrolase

Leukotriene B4 (LTB4) is a pro-inflammatory mediator that has been implicated in the pathogenesis of a number of diseases including inflammatory bowel disease (IBD) and psoriasis. Since the action of LTA4 hydrolase is the rate-limiting step for LTB4 production, this enzyme represents an attractive pharmacological target for the suppression of LTB4 production. From an in- house screening program, SC-22716 (1, 1-[2-(4- phenylphenoxy)ethyl]pyrrolidine) was identified as a potent inhibitor of LTA4 hydrolase. Structure-activity relationship (SAR) studies around this structural class resulted in the identification of a number of novel, potent inhibitors of LTA4 hydrolase, several of which demonstrated good oral activity in a mouse ex vivo whole blood assay.

Fungal Pigments, 49. - Synthesis of Grevillins and Related 2H-Pyran-2,5(6H)-diones

A convergent synthesis of grevillins 1 starts from diazoesters 6 which are converted into 3-aryl-2-oxopropyl ethyl oxalates 4 via bromoketones 7.Cyclization of 4 leads to pyrandiones 2 which are condensed with aromatic aldehydes to yield 4-aryl-2-benzylid